Mineralys Therapeutics Inc
MLYSHealthcare|Biotechnology|USA
$28.38
-0.58 (-2.00%)
Tangible Book
$7.74
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05968430 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | Hypertension | P3 | Active | 1,076 | Open-label | lorundrostat, Placebo |
| NCT06153693 Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension | Hypertension | P3 | Completed | 1,083 | RCT, Double-blind | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 |
| NCT05001945 Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension | Hypertension, Renal | P2 | Completed | 200 | RCT, Double-blind | MLS-101 (Part I), MLS-101 (Part II) |
| NCT06150924 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria | Chronic Kidney Disease | P2 | Completed | 60 | RCT, Double-blind | Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD |
| NCT06785454 A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension | Obstructive Sleep Apnea, Hypertension | P2 | Completed | 48 | RCT, Double-blind | Lorundrostat, Placebo |
| NCT05769608 A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen | Hypertension | P2 | Completed | 285 | RCT, Double-blind | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 |